In common with all countries in the developed world, the United Kingdom is experiencing a dramatic increase in the incidence of diabetes and chronic kidney disease. The most common cause of renal impairment is diabetes. The evolution of diabetic nephropathy is usually predictable with evidence-based interventions available at each stage. This review examines this evidence and gives practical advice on the management of patients with diabetic nephropathy.Br J Diabetes Vasc Dis, 2008; 8: 272—277
Ritz E., Rychlik I., Locatelli F., Halimi S.End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis1999;34:795-808.
2.
Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int2003;63:225-32.
3.
Allen KV, Walker JDMicroalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care2003;26:2389-91.
4.
Gambaro G., Kinalska I., Oksa A. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol2002;13:1615-25.
5.
The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med1993;329:977-86.
6.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
7.
Bilous R.Microvascular disease: what does the UKPDS tell us about diabetic nephropathy ? Diabet Med2008; 25(suppl 2):25-9.
8.
National Institute for Health and Clinical Excellence.The management of type 2 diabetes. London: NICE, 2008.
9.
Keller CK, Bergis KH, Fliser D., Ritz E.Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol1996;7:2627-35.
10.
Ritz E., Orth SRNephropathy in patients with type 2 diabetes mellitus. N Engl J Med1999;341:1127-33.
11.
Ruggenenti P., Fassi A., Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med2004;351:1941-51.
12.
Patel A., MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370:829-40.
13.
Huang XR, Chen WY, Truong LD, Lan HYChymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol2003;14:1738-47.
14.
Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001;345:870-8.
15.
Makino H., Haneda M., Babazono T. et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care2007;30:1577-8.
16.
Mogensen CE , Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ2000; 321:1440-4.
17.
Parving HH, Persson F., Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy . N Engl J Med2008;358:2433-46.
18.
Barnett AH, Bain SC, Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med2004;351:1952-61.
19.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med1993;329:1456-62.
20.
Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851-60.
21.
Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
22.
Staessen JA , Wang JG, Ginocchio G. et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens1997;15:1579-92.
23.
Parving HH, de Zeeuw D., Cooper ME et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol2008;19:771-9.
24.
Penno G., Chaturvedi N., Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes1998 ;47:1507-11.
25.
Fujisawa T. , Ikegami H., Kawaguchi Y. et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia1998;41:47-53.
26.
Ritz E., Ogata H., Orth SRSmoking: a factor promoting onset and progression of diabetic nephropathy . Diabetes Metab2000;26(suppl 4): 54-63.
27.
Wanner C., Krane V., Marz W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005; 353:238-48.
28.
Tonolo G., Ciccarese M., Brizzi P. et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care1997;20:1891-5.
29.
Pedrini MT, Levey AS, Lau J. et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med1996;124:627-32.
30.
Klahr S., Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med1994;330:877-84.